Daunorubicin

Core Binding Factor Acute Myeloid Leukemia

National Cancer Institute (NCI)Phase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

7 Active assets in the Core Binding Factor Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Cytosin-Arabinosid National Cancer Institute (NCI)	Phase 2	B
Dasatinib National Cancer Institute (NCI)	Phase 2	B
Decitabine Children's Hospital of Soochow University	Phase 2	CCC
Venetoclax National Cancer Institute (NCI)	Phase 2	CCC
Azacitidine Children's Hospital of Soochow University	Phase 2	CCC

View all 10 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant

BBB

Indicative ·

78 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

77 / 100

acute monocytic leukemiaDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.